ING Groep NV Reduces Holdings in Boston Scientific Corporation (BSX)

ING Groep NV trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 36.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 30,566 shares of the medical equipment provider’s stock after selling 17,848 shares during the quarter. ING Groep NV’s holdings in Boston Scientific were worth $758,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the business. Bollard Group LLC raised its holdings in shares of Boston Scientific by 0.3% during the fourth quarter. Bollard Group LLC now owns 33,854,117 shares of the medical equipment provider’s stock worth $839,244,000 after purchasing an additional 118,050 shares during the period. American Century Companies Inc. raised its holdings in shares of Boston Scientific by 28.9% during the third quarter. American Century Companies Inc. now owns 10,496,489 shares of the medical equipment provider’s stock worth $306,183,000 after purchasing an additional 2,352,297 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Boston Scientific by 0.9% during the third quarter. Wells Fargo & Company MN now owns 9,240,477 shares of the medical equipment provider’s stock worth $269,545,000 after purchasing an additional 82,709 shares during the period. Boston Partners raised its holdings in shares of Boston Scientific by 3.8% during the fourth quarter. Boston Partners now owns 7,475,797 shares of the medical equipment provider’s stock worth $185,325,000 after purchasing an additional 276,390 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Boston Scientific by 3.6% during the third quarter. Legal & General Group Plc now owns 6,760,998 shares of the medical equipment provider’s stock worth $197,195,000 after purchasing an additional 232,309 shares during the period. 89.84% of the stock is currently owned by institutional investors.

A number of analysts have weighed in on the stock. Jefferies Group reissued a “neutral” rating on shares of Boston Scientific in a report on Friday, February 2nd. Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th. TheStreet raised shares of Boston Scientific from a “c+” rating to a “b” rating in a report on Thursday, January 18th. Canaccord Genuity reissued a “buy” rating on shares of Boston Scientific in a report on Wednesday, January 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $31.00.

Boston Scientific Corporation (NYSE BSX) opened at $26.81 on Thursday. The company has a market cap of $35,854.15, a PE ratio of 383.00, a price-to-earnings-growth ratio of 1.89 and a beta of 0.81. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. Boston Scientific Corporation has a 52 week low of $23.29 and a 52 week high of $29.93.

Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.34. The firm had revenue of $2.41 billion for the quarter, compared to analysts’ expectations of $2.39 billion. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. Boston Scientific’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the company earned $0.30 EPS. equities research analysts forecast that Boston Scientific Corporation will post 1.37 earnings per share for the current year.

In related news, insider Valley Gold Master Fund L. Sun bought 408,006 shares of the stock in a transaction on Tuesday, November 28th. The shares were purchased at an average price of $0.45 per share, with a total value of $183,602.70. Also, SVP David A. Pierce sold 8,763 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $27.74, for a total transaction of $243,085.62. Following the transaction, the senior vice president now directly owns 24,201 shares in the company, valued at approximately $671,335.74. The disclosure for this sale can be found here. In the last three months, insiders have sold 177,032 shares of company stock worth $4,648,733. 0.74% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “ING Groep NV Reduces Holdings in Boston Scientific Corporation (BSX)” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.chaffeybreeze.com/2018/02/15/ing-groep-nv-reduces-holdings-in-boston-scientific-corporation-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply